Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
TARRYTOWN, N.Y., March 16, 2015 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) today announced its results of operations for the fourth quarter and year-end 2014. "We have...
-
TARRYTOWN, N.Y., March 9, 2015 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc., (Nasdaq:PGNX), an oncology company focused on developing innovative ways to target and treat prostate cancer,...
-
TARRYTOWN, N.Y., March 2, 2015 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc., (Nasdaq:PGNX) announced today that long-term follow-up data from its ongoing pivotal Phase 2 Study of AzedraTM in...
-
TARRYTOWN, N.Y., Feb. 26, 2015 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc., (Nasdaq:PGNX) today announced the presentation of the full results from its Phase 2 clinical study of PSMA ADC in...
-
TARRYTOWN, N.Y., Feb. 23, 2015 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc., (Nasdaq:PGNX) announced today that the full results from its Phase 2 clinical study of PSMA ADC in patients with...
-
TARRYTOWN, N.Y., Feb. 17, 2015 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc., (Nasdaq:PGNX), an oncology company focused on the development of innovative approaches to targeting and treating...
-
TARRYTOWN, N.Y., Feb. 3, 2015 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc., (Nasdaq:PGNX), an oncology company focused on the development of innovative approaches to targeting and treating...
-
First Patient Dosed in the Resumed Study Company Expects to Complete Enrollment by Year-End 2015 TARRYTOWN, N.Y., Jan. 23, 2015 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc., (Nasdaq:PGNX)...
-
TARRYTOWN, N.Y., Dec. 2, 2014 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) today announced that data from the Phase 2 trial of its PSMA imaging agent candidate, 1404, will be...
-
TARRYTOWN, N.Y., Nov. 11, 2014 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc., (Nasdaq:PGNX), an oncology company focused on developing innovative ways to target and treat cancer, announced today...